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Melanocytes and keratinocytes were analyzed for potential roles of p53, p73, and p63 tumor suppressor family
proteins and of malignancy-speciﬁc gene expression changes in the etiology of multi-step cancer. Melanocytes
expressed DNp73a, two p63 isoforms and p53. Although p21 and Noxa mRNA levels increased following DNA
damage, p53 family member binding to p21 and Noxa DNA probes was undetectable, suggesting p53 family-
independent responses. In contrast, keratinocytes expressed multiple isoforms each of p73 and p63 that were
induced to bind p21 and Noxa DNA probes after ionizing (IR) or after ultraviolet B (UVB) irradiation, correlating with
p21 and Noxa mRNA induction and with apoptosis. Interestingly, IR-resistant malignant melanocytes and
keratinocytes both exhibited Noxa mRNA induction after UVB treatment, correlating with DNA binding of p53 family
proteins to the Noxa probe only in keratinocytes. To uncover other malignancy-speciﬁc events, we queried mouse
initiated keratinocyte clones for early changes that were exacerbated in malignant derivatives and also
differentially expressed in human advanced melanoma versus normal melanocytes. Using a new method for
ranking and normalization of microarray data for 5000 probe sets, 27 upregulated and 13 downregulated genes
satisﬁed our query. Of these, the majority was associated with late-stage human cancers and six were novel genes.
Thus, clonal lineage mouse models representing early through late cancer progression stages may inform the
focus on early, potentially causal events from microarray studies of human cancers, facilitating prognosis and
molecular therapy.
Key words: keratinocytes/melanocytes/p53 protein/p63 protein/p73 protein
J Investig Dermatol Symp Proc 10:142 –152, 2005
A fraction of non-melanoma (less than 0.5%) and melanoma
(less than 13%) or approximately 10,600 skin cancers per
year turn deadly and, at present, we have no way to dis-
tinguish them. In the spirit of the Montagna Symposium
2004 theme ‘‘Keratinocyte and melanocyte cancers of skin:
interactive pathways,’’ we compared pathways to cancer in
non-melanoma and melanoma skin cancers in two re-
spects: (1) p53 family member proteins’ presence and ac-
tivities within in vitro/in vivo models in the mouse and (2)
global gene expression profiles between a mouse squa-
mous cell carcinoma (SCC) carcinogenesis model and hu-
man melanoma. With the underlying hypothesis that the
deadliest examples of each cancer type might have certain
genes or pathways in common, we explored the possibil-
ities for common pathways in cancer development between
these different skin cell types and used mouse models en-
compassing early and late stages of cancer to inform se-
lection of candidate genes from microarray analysis of late-
stage human cancer.
p53 Family in Melanocytes versus
Keratinocytes: Introduction
The p53 gene is generally wild-type in human melanomas of
skin. Whereas p53 genes can be mutant in up to a quarter
of advanced human melanomas, recent functional studies of
p53 mutant protein activity in various tumors have revealed
that over 70% of the mutations in the p53 gene naturally
occurring in human melanoma retain X50% of wild-type
p53 protein function (Soussi et al, 2005). Yet, inactivation of
the p53 pathway is believed to be required in essentially all
human cancers, and studies of mouse melanoma models
indicate that p53 pathway inactivation is required for me-
lanoma even at early stages. Besides p53 gene mutation
complementary to Ha-Ras mutations, inactivation of p53
protein can occur by INK4A loss and the resulting increase
of the Mdm2 protein that degrades p53 (Bardeesy et al,
2001). INK4A/ARF and CDK4 loss or mutation are prevalent
in sporadic human melanoma and are responsible for 25%–
40% of hereditary disposition in human melanoma patients
(Ghiorzo and Bianchi Scarr, 2003). Loss of APAF gene ex-
pression is a common mechanism of inactivating the p53
effector (downstream) signaling pathway in melanoma (So-
engas et al, 2001). The discovery of other p53 family genes
p63 and p73, each with multiple isoforms and activities, and
Abbreviations: IR, ionizing radiation; PRNP, positional ranking and
normalization procedure; SCC, squamous cell carcinoma; UVB,
ultraviolet B
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their regulation of many of the same downstream genes as
p53, has opened other avenues for modulation of p53 ac-
tivities. Isoform expression and activities in a given cell type
are particularly important because of multiple levels of po-
tential regulation among p53 family proteins. TA isoforms
are transcriptionally active whereas DN isoforms lack an N
terminal transcriptional activation domain (Tuve et al, 2004).
The DN isoforms of p73 mRNA are positively regulated by
transcriptionally active p53 and p73 and negatively regulate
p73, p63, and p53 TA isoforms, establishing a feedback
regulation. Wild-type p63 and p73 isoforms can oligomerize
with each other and with mutant p53 (Chan et al, 2004). As
noted above, p73 and p63 genes are wild-type in a broad
sampling of human tumors, including melanoma. As yet,
there are few reports of p73 and p63 expression in me-
lanoma. The isoform specificity of expression in human
tumors is just beginning to be studied and none of these
studies have investigated all three family members and their
isoform expression in the same samples. In one report, total
p63 was expressed very little in normal melanocytes and
only in a small fraction (less than 2%) of human melanomas
on a tissue microarray compared with almost 12% with p53
expression (Brinck et al, 2002). The importance of p53 and
p73 pathways in melanoma, however, is suggested by find-
ings that apoptosis induced by oligonucleotide homologous
to the telomere 30 overhang sequence (T-oligo) in tumors
from human melanoma cell lines acts through p53 and p73
(Puri et al, 2004).
p53 Family in Melanocytes versus
Keratinocytes: Results and Discussion
We sought to determine the status of three p53 family
member proteins, their DNA-binding activities, and p53
downstream gene expression in melanocytes and me-
lanoma, compared with a keratinocyte carcinogenesis mod-
el. Mouse models of melanoma and SCC development
provide abilities for manipulation of gene expression and
sampling of tissue stages during multi-step cancer devel-
opment in vitro and in vivo, which is not possible in humans
(Fig 1). The keratinocyte model used in this study is com-
prised of clonally derived non-transformed, initiated and
malignant cell derivatives (SCC) from mouse epidermis
(Kulesz-Martin et al, 1985, 1986, 1988). These cells lack Ha-
Ras mutations (Schneider et al, 1993) and have wild-type
p53 genes, as do at least half of human cancers. Although
the p53 gene remains wild-type, p53 protein function is de-
fective at malignant conversion (Knights et al, 2003). The
non-transformed, transformed, and malignant melanocyte
lines were independently derived from transgenic mouse
lines as reported previously (Broome et al, 1999; Gause
et al, 1997). The malignant cells were derived from
transgenic mice expressing mutant human Ha-Ras genes
in melanocytes. The tumors in the melanoma model also
lack p16 (INK4A) expression (Gause et al, 1997). We analy-
zed this melanoma model for expression of p53, p63,
and p73 proteins, for the DNA-binding capacity of these
proteins to probes containing the cell cycle-associated
p21 and apoptosis-associated Noxa mouse promoter
sequences and for upregulation of p21 protein and Noxa
mRNA in response to ionizing radiation (IR) or ultraviolet B
(UVB) light.
Expression of p53 family isoforms in mouse melanoma
model The total steady-state levels of expression of p73,
p63, and p53 proteins were detected by immunoblotting as
shown in Fig 2. Non-transformed and initiated keratinocytes
(initiated 03C is in lane 1 shown for comparison with
the melanocyte model) expressed three isoforms of p73,
transcriptionally active form TAp73a, dominant-negative
DNp73a, and an unidentified lower molecular weight p73
isoform. Keratinocytes expressed four isoforms of p63,
TAp63a, DNp63a, TAp63b (all identified by apparent mo-
lecular weight and isoform-specific RT-PCR) and a lower
molecular weight form likely to be either a TAp63g or
DNp63b. Melanocytes expressed only one p73 isoform;
dominant-negative DNp73a. Untreated YMM and trans-
formed JMM (lanes 2 and 5) expressed DNp73a at similar
basal levels. Untreated melanoma 1984-1 (lane 8) ex-
pressed elevated DNp73a compared with non-transformed
YMM and initiated JMM melanocytes. Although p53 ex-
pression is elevated in about 25% of human melanomas,
consistent with abnormal regulation of degradation of mu-
tated or defective wild-type p53 proteins, elevated steady-
state levels of wild-type p73 and p63 proteins have been
found in a variety of human cancers (Moll and Slade 2004),
consistent with the elevated expression seen in 1984-1
mouse melanoma cells. Melanocytes expressed two iso-
forms of p63, the TAp63b and either TAp63g or DNp63b (yet
to be determined by isoform-specific RT-PCR), and these
were not elevated in melanoma 1984-1 cells. The predom-
inant p63 form varied among the melanocyte lines, with the
lower molecular weight form predominant in non-trans-
formed YMM and melanoma 1984-1 and the higher molec-
ular weight form predominant in transformed JMM. None of
the p63 or p73 protein forms were induced by treatment
with IR or UVB. p53 was expressed in YMM with little re-
sponse to treatment (IR 1.7-fold untreated, UVB 1.3-fold).
Basal p53 expression was reduced in transformed JMM
and in melanoma 1984-1 relative to YMM but was restored
Non-transformed Initiated/Transformed
SCC
Melanoma
YMM JMM 1984-1
DMBA
291 03C 03RDMBAKeratinocytes
Melanocytes
Figure1
Cellular relationships within the mouse clonal model of epidermal
carcinogenesis and the mouse TP-Ha-ras melanoma model. Non-
transformed keratinocyte clonal cell strain (291), derived from the ep-
idermis of normal Balb/C newborn mice was treated with 7,12-dime-
thylbenz[a]anthracene (DMBA) to derive initiated clone 291.03C (03C)
based on a defect in the terminal differentiation response to extracel-
lular Ca2þ . Clone 03C produced squamous cell carcinoma (SCC) in
mice at low frequency, from which SCC-producing cell line 291.03R
(03R) was derived. The 03R line produces skin SCC in 100% of grafts to
athymic nu/nu mice and these metastasize to the lung and regional
lymph nodes. YMM (non-transformed) melanocytes were derived from
the skin of 5-d-old yellow-coated mice on a C57BL/6 background.
JMM (transformed) from TP-vjun mice, and 1984-1 melanoma from TP-
Ras mice treated with DMBA.
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weakly in response to IR in JMM (1.8-fold untreated JMM)
and restored to at least normal expression in JMM and
1984-1 exposed to UVB (16-fold untreated JMM and 12-
fold untreated 1984-1, respectively). A regulator of p53,
Mdm2, has opposing effects on p53 (degradation) and p73
(stabilization) (Ongkeko et al, 1999). Although Mdm2 was
not examined in the melanocytes in our study, increased
levels or activity of Mdm2 in transformed or malignant me-
lanocytes is one possible explanation for the observed in-
crease in the basal levels of p73 protein correlated with
decreased p53 protein in this model. The ability of IR or UVB
to induce p53 in these cells suggests that a p53-stabilizing
pathway in response to stress is retained in spite of reduced
basal levels.
In order to determine whether stabilization of total p53
family proteins leads to increased DNA binding and whether
DN isoforms might negatively regulate transactivation of
p53 downstream genes by binding to their promoters, we
assessed the capability of the p53 family proteins for DNA
binding to probes containing endogenous DNA sequences
of the cell cycle-associated promoter p21 and apoptosis-
associated promoter Noxa.
DNA-binding activity of p53 family proteins in me-
lanocytes In keratinocytes, all three p53 family members
demonstrated activity for DNA binding to the p21 probe (Fig
3). Selective binding of p63 to the Noxa probe was corre-
lated with keratinocyte apoptosis (data not shown). In spite
of the expression of DNp73a, TAp63b, TAp63g or DNp63b
and p53 in non-transformed YMM melanocytes, none of
these endogenous proteins showed specific DNA-binding
capability to p21 or Noxa DNA probes in the DNA-binding
assays, either from untreated cells or cells treated with IR or
UVB (data not shown). DNA binding of p53 protein to p21
but not Noxa probes was robust in JMM cells, unchanged
after IR treatment, and elevated after UVB treatment (data
not shown), consistent with total protein as shown in Fig 2.
Although at least one isoform of all three p53 family mem-
bers was present in the 1984-1 melanoma, only the dom-
inant-negative DNp73a was detected specifically bound to
DNA probes of downstream genes p21 and Noxa, and only
in cells treated with IR (Fig 3, lanes 11 and 12, compared
with non-specific binding to control DNA probe lacking p53-
binding sites in lane 10). The occupation of target gene
promoters by a dominant-negative form of p73 could inhibit
activation of p21 or Noxa by IR in these cells. To address
this issue we examined p21 and Noxa mRNA levels.
Activation of p53 downstream genes in melanocytes
YMM cells demonstrated responses to both IR and UVB by
induction of p21 mRNA as detectable by means of quan-
titative real-time PCR (Fig 4, left panel). Activation of these
promoters in the cells would be consistent with lack of DNA
binding of the negative regulatory forms of p73 or p63 in
YMM cells to the p21 DNA probe. But, the induction of p21
mRNA in YMM cells by IR and by UVB occurred without
DNA binding of any isoforms of p73, p63, or p53 in YMM.
The lack of Noxa mRNA induction by IR or UVB in YMM
cells correlated with lack of p53 family member DNA bind-
ing. Inactivity of the Noxa promoter in response to IR or
UVB, however, was not because of negative regulation by
DNp73 or DNp63 forms. The induction of p21 mRNA by IR
without DNA-binding activity of a p53 family member in
YMM cells, and the finding reported by Brian Nickoloff in
this volume and by Qin et al (2004) that notch transcription
factor induces Noxa independent of p53 suggest that in-
duction of Noxa is not only p53 independent in melanocytes
but also p53 family independent.
Thus, DNA binding of DN forms of p73 or p63 is not
required to negatively regulate activation of Noxa in the
melanocytes. It is possible, however, that the dominant-
negative forms DNp73a and potentially DNp63b that pre-
dominate in YMM negatively regulate Noxa or other p53
downstream genes without requiring complex formation
with DNA. Further, it is possible that a necessary transcrip-
tion factor for Noxa is absent. The lack of DNA binding by
p73 or p63 isoforms in transformed melanocytes JMM, and
lack of inducibility of the observed p53 DNA binding to the
p21 probe in these cells are consistent with loss of function
of p53 family members in JMM. This was confirmed by lack
Figure 2
p53 family expression in non-transformed YMM, transformed
JMM, and melanoma cell line 1984-1. Melanocytes were cultured in
RPMI 1640 plus 10% fetal bovine serum, and 1% antibiotic–antimyco-
tic (Invitrogen, Carlsbad, California). YMM and JMM cells were further
supplemented with 200 nM 12-O-tetradecanoyl-phorbol-13-acetate
(TPA) and 200 pM cholera toxin. Cells were untreated (UT) or harvested
3 h following treatment with ionizing radiation (IR) (4 Gy), or 5 h fol-
lowing treatment with ultraviolet B radiation (UVB) (135 J per m2). Whole
cell lysate aliquots of 40 mg (for p53 and p73) or 10 mg (for p63) were
separated by 8% SDS-PAGE and transferred to nitrocellulose for
immunoblotting as reported previously (Wu et al, 1997). Proteins were
reacted with specific antibodies to p53 (pAb122), p63 (4A4 monoclonal
from Santa Cruz, Santa Cruz, California, detects all isoforms), p73
(monoclonal 5B1288 from Imgenex (San Diego, California), detects all
isoforms), or actin (C-2 -Santa Cruz) as loading control and visualized
by chemiluminescence (ECL [Perkin Elmer, Boston, Massachusetts]
Isoforms of p73 and p63, as well as p53 in melanocytes are shown in
comparison with untreated initiated epidermal keratinocyte line 03C
(lane 1). Putative p73 isoform identification is based upon apparent
molecular weight alone (labeled in parentheses). p63 isoform identifi-
cation is based, in addition, upon RT-PCR using primers specific to
exon/intron junctions of a, b, and g forms for the 30 primer, and TA
versus DN specific junctions for the 50 primers (Dennis Roop, personal
communication) as follows: M63DN.F (TTGTACCTGGAAAACAATG),
M63TA.F (TCGCAGAGCACCCAGACA), 63SEQ.2F (CCACCACAGGTT
GGCACTG), 63SEQ.3F (CCAGATGATGAGCTGCTGTACC), M63-2R
(GCATCGTTTCACAACCTCG), M634R (TAGTCCAGGCATGATGAG),
M63-bR (CAGACTTGCCAAATCCTGAC), and M63gR (GGCTCCA-
CAAGCTCATTC). To detect the shorter N terminal or C terminal p63
fragments, we used 40 cycles of 921C for 30 s, 561C for 1 min, and
721C for 1 min with a 15-min extension time at 721C. To detect the long
fragments (i.e., TAa, TAb, etc.), we used 40 cycles of 921C for 1 min,
561C for 2 min, and 72 1C for 3 min with a 15-min extension time at
721C. Myc-tagged p63 plasmids of the various isoforms are used as
positive controls for the RT-PCR reactions.
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of induction of p21 or Noxa RNA expression after treatment
of JMM cells with IR or UVB (data not shown).
DNA-binding studies in 1984-1 melanoma supported
regulation of p21 and Noxa transcription by p53 family
members. Where DNp73a-specific binding to the p21 DNA
probe was induced after IR treatment of 1984-1 melanoma
cells (Fig 3, lane 11), p21 mRNA was not induced (Fig 4,
right panel). Under the same conditions, DNp73a in YMM
cells was not bound to p21 DNA probe and p21 RNA was
induced (Fig 4, left panel). Consistent with negative regu-
lation of Noxa and p21 response to IR in 1984-1 melanoma
cells, DNp73a bound to Noxa and p21 DNA probes and
neither p21 nor Noxa mRNA were induced by IR (Fig 4, right
panel, second and 5th bar from left). Where p21 mRNA was
strongly induced by UVB in 1984-1 melanoma cells (Fig 4,
right panel, third bar from left), the DNp73a was not specif-
ically bound to the p21 DNA probe (Fig 3, lane 15 indistin-
guishable from lane 14 control), and p53-specific binding to
the p21 DNA probe was strongly induced (Fig 3, lane 15).
Summary, Conclusions, and Future Studies
of p53 Family in Melanocytes
Keratinocytes and melanocytes of mouse cell culture mod-
els expressed different patterns of p53 family protein iso-
forms, consistent with the tissue specificity of isoform
expression, as summarized for mouse keratinocyte and
melanocyte models in Fig 5. Both cell types expressed
DNp73a. In melanocytes, this was the only p73 isoform ex-
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Figure 4
mRNA expression of p53 target genes
p21 and Noxa RNA was isolated from
YMM (control) and 1984-1 (melanoma)
cells 24 h after treatment with ionizing
radiation (IR) (4 Gy), or ultraviolet B
radiation (UVB) (135 J per m2). The
cDNA was generated using AMV reverse
transcriptase (Roche, Indianapolis, Indi-
ana) and random hexamer primers (In-
tegrated DNA Technologies). Relative
expression levels of p53 target genes
p21 and Noxa were analyzed by quan-
titative real time PCR using SYBR-Green
I reporter dye in a 7900HT thermocycler
(Applied Biosystems Inc., Foster City, California) as described previously (Horn et al, 2004). Gene-specific primers for p53 target genes were mouse
p21 [(CCATGTCCAATCCTGGTGATG) and (CGAAGAGACAACGGCACACTT)] and mouse Noxa [(ACTGTGGTTCTGGCGCAGAT) and (TGAGCA-
CACTCGTCCTTCAAGT)], and these data were normalized to expression levels of 18S RNA [(CGGCTACCACATCCAAGGAA) and (CCTGTATTGT-
TATTTTTCGTCACTACCT)]. Data are shown relative to gene expression levels in untreated YMM and untreated 1984-1 cells, respectively. Each
sample was run in triplicate on three separate plates. Error bars depict standard deviation from the mean.
Figure 3
DNA-binding capability of endogenous p53 family proteins from mouse melanoma 1984-1, and 03C keratinocyte cell lines assayed by DNA
affinity immunoblotting (DAI). DAI of whole-cell lysates incubated with biotinylated DNA probe in vitro has been described (Liu et al, 2001; Knights
et al, 2003). Aliquots of 200 mg lysate from untreated (UNT) cells or cells harvested 3 h following treatment with ionizing radiation (IR) (4 Gy), or 5 h
following treatment with ultraviolet B radiation (UVB) (135 J per m2) were incubated with specific biotinylated probe DNA sequences of the mouse
p21 or noxa promoter or to probe sequences lacking p53-binding sites (Con). DAI probes were synthesized by PCR using a mouse keratinocyte
genomic DNA template, and the primers indicated and probe sequences were verified as wild-type by sequencing at the OHSU Cancer Institute
sequencing core facility.
Probe Length (bp) 50 biotinylated PCR primer 30 PCR primer
Con 164 50TCTAAAGTCCCTGCCTTCC30 50CGAGATAGTTCAGTGAATGCC30
p21 158 50GCATCAGTCCTCCCATCC30 50GCCCCACCTCTTCAATTCC30
Noxa 199 50TGCCCCAGCAATGGATAC30 50GAACCGAGCGAAGTGGAG30
The resulting DNA:protein complexes were precipitated with magnetic streptavidin beads (Promega, Madison, Wisconsin). Proteins were separated
by 8% SDS-PAGE and reacted with specific antibodies as in the legend of Figure 2. Direct immunoblot lanes contain 40 mg of protein. Similar DAI
analysis of YMM and JMM proteins indicated no DNA binding of p73 or p63. DNA binding of p53 was absent in YMM and JMM except for binding to
the p21 probe present but unresponsive to treatment in IR-treated JMM only.
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pressed, whereas keratinocytes also expressed a transcrip-
tionally active form TAp73a and an additional unidentified
lower molecular weight isoform. Both keratinocytes and
melanocytes expressed TAp63b and a lower molecular
weight isoform, either TAp63g or DNp63b, but in YMM non-
transformed and 1984-1 melanoma, this lower molecular
weight form predominated, whereas TAp63a and TAp63b
isoforms predominated (in that order) in keratinocytes. In
initiated 03C keratinocytes, induction of p21 and Noxa
mRNA correlated with induction or maintenance of p63 and
p53 DNA binding to their respective DNA probes, suggest-
ing p63- and p53-dependent transactivation of these genes
in response to IR and UVB. Loss of induction of p63 and
p53 DNA binding by IR in 03R SCC derivatives of 03C-
initiated cells correlated with loss of respective mRNA
induction and with failure to undergo growth arrest or
apoptosis (data not shown). In both 1984-1 melanoma and
03R SCC derivatives, however, Noxa mRNA was induced
by UVB. In the SCC-producing keratinocytes 03R, this cor-
related with p63 and p53 DNA binding to the Noxa probe
and with apoptosis (data not shown). In the melanoma line,
however, Noxa mRNA induction occurred without any p63
isoform or p53 protein binding to the Noxa DNA probe. UVB
induction of Noxa mRNA may have been facilitated by lack
of a dominant-negative DNp73a isoform DNA binding to the
Noxa promoter. Although UVB induction of p21 RNA in
YMM cells was independent of p53, p73, or p63 binding to
DNA, UVB induction of p21 RNA in the 1984-1 melanoma
cells correlated with the overall stabilization of p53 protein
and DNA binding of p53 to the p21 probe.
The UVB induction of Noxa in the UVB-treated 1984-1
melanocytes without detectable binding of endogenous
p73, p63, or p53 proteins from melanocytes to the Noxa
promoter sequence DNA probe is consistent with the find-
ings of the Nickoloff laboratory that Noxa induction can be
p53 independent in melanocytes (Qin et al, 2004). Further,
the presence of p73, p63, and p53 in non-transformed YMM
melanocytes without any detectable DNA binding to either
the p21 or Noxa DNA probes leads us to conclude that p21
induction in these non-transformed melanocytes is not only
p53 independent but also p73 and p63 independent.
These studies show cell type specificity of p53 family
proteins expressed in melanocytes at different stages of
melanoma progression, the DNA-binding capability of the
expressed isoforms for a cell cycle versus apoptosis-
related promoter, and the responsiveness to IR or UVB ra-
diation. Chromosome immunoprecipitation, however, will be
necessary to determine specifically which p53 downstream
promoters are occupied in cells by each p73, p63, and p53
isoform for selective regulation of p53 family targets. From
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Figure 5
Schematic representation of the p53 family member response to ionizing radiation (IR) or ultraviolet radiation B (UVB) in 03C and 03R
keratinocytes, and YMM and 1984-1 melanocytes. Reading from top to bottom, the schematic shows which p53 family member proteins are
expressed before and after treatment with IR or UVB, followed by which p53 family members bind DNA in untreated cells or cells treated with IR or
UVB (showing only those p53 family members that changed). The corresponding cellular responses in terms of p21 and noxa gene transactivation,
and cell behavior follow. The complete p53 family member expression profile can be seen in Figure 2 for melanocytes and 03C keratinocytes. ‘‘All
isoforms’’ for p73 include TAa, and DNa, and p63 includes TAa, DNa, TAb, and (TAg or DNb). The 03R keratinocyte expression profile is similar to 03C
except that p63 (all isoforms) are slightly reduced and p73 (all isoforms) are dramatically reduced.
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the current results, it is possible that the dominant-negative
forms DNp73a and potentially DNp63b predominating in
melanocytes play a differential negative role in Noxa mRNA
induction in YMM and/or that a necessary transcription
factor for Noxa is absent. It is still possible, however, that
p53 family members, such as TAp73 or TAp63 isoforms,
play a role in the induction of these or other p53 down-
stream genes if expressed in melanocytes at other stages or
conditions beyond the scope of this study.
Both g and d p73 variants are reportedly expressed in
human primary keratinocytes and different tumor cell lines,
including melanoma (De Laurenzi et al, 1998). The DN-p73
generated from the second promoter was the predominant
isoform in benign nevi, similar to our findings in the YMM
non-transformed cells. In the same study, however, TA-p73D
isoform increases were associated with melanoma progres-
sion (Tuve et al, 2004). The lack of induction of p73 by UVB
in our study supports a previous report that expression of
p73 and other cellular proliferation-related proteins was not
changed by the UVB irradiation (Zhang and Rosdahl, 2003).
The expression of DNp63 has been described in the basal
cell compartment of squamous epithelium. The counterbal-
ance between TAp63 and DNp63 isoforms appears to play
an essential role in epidermal stratification and differentia-
tion (Yang et al, 1998; Koster et al, 2004). The occupation of
target gene promoters by a dominant-negative form of p73
observed in the current study is an intriguing plausible
mechanism for failure of IR to activate p21 or Noxa and for
notorious melanoma IR resistance.
Comparative Gene Expression Proﬁling of
Cancer in Keratinocytes and Melanocytes:
Introduction
A global approach is needed to uncover changes in gene
expression that characterize progression or make good
prevention or therapeutic targets for melanoma or SCC.
Because limited samples of human cancer progression are
available, often late in the process, models of cancer de-
velopment that encompass early as well as late stages are
needed. These offer advantages to uncover potentially
causative early changes that are also essential in late-stage
disease, and thus potentially good targets for molecular
therapy. We previously reported differences in gene ex-
pression between a non-transformed keratinocyte clone
and two clonal derivatives: 03C, a precursor to SCC that
metastasizes to lung and lymph node and 09C, a precursor
to benign (papilloma) (Wang et al, 2002). Since then, we
have extended the study of gene expression in this kera-
tinocyte clonal lineage model to the metastatic SCC deriv-
ative of 03C, 03R. As with most microarray experiments,
however, selecting likely gene candidates for prediction of
outcomes and potential molecular therapeutic targets is a
challenging task.
The results from two microarray experiments, one using
the keratinocyte clonal lineage carcinogenesis model in the
mouse (Wang et al, 2002) and the other studying primary
cultures of human melanoma (Hoek et al, 2004), were re-
analyzed to isolate a subset of changes in common to me-
lanoma and non-melanoma skin cancers. This reanalysis
makes use of mouse models in which early stages are
available to inform potential causative gene changes in hu-
man cancers for which only a single time point is generally
available. Underlying our query design is the rationale that
gene expression changes that occurred early (as can be
detected in the mouse model) and were maintained or fur-
ther increased/decreased in the malignant stage (in both
mouse and human models) were more likely to be causal in
nature. We posit that (1) as in the case of Bcr-Abl in chronic
myelogenous leukemia in blood cancers (Deininger et al,
2005), these causal events make the best targets for novel
molecular-targeted therapy development and (2) certain
of these cancer initiating/causal events will occur in com-
mon in malignant skin cancers between keratinocytes and
melanocytes.
A new method of ranking and normalization of the genes
from a microarray experiment was used to compare the
mouse keratinocyte carcinogenesis model with human me-
lanoma and normal melanocyte cell cultures. The new strat-
egy includes steps for ranking genes and for normalizing
data, and is thus called the ‘‘Positional Ranking and Nor-
malization Procedure (PRNP).’’ A full description of this
method will be presented in another publication (Pelz and
Sears, in preparation).1 Briefly, PRNP was implemented us-
ing ‘‘R’’ (Team RDC, 2004), an open source statistical com-
puting environment. For each sample, the method first sorts
the probe sets in ascending order based on the expression
level reported by Affymetrix MAS 5.0 software. Each probe
set is given a rank number based on its sorted order in the
sample. Next, PRNP makes pairwise comparisons between
samples by assigning positive or negative positional ‘‘shifts’’
to each probe set based on the difference in that probe set’s
rank between the two samples. Probe sets with small or no
shifts represent the invariant genes between samples that
we used to normalize the data. When calculating fold
changes, we first normalize all samples to an idealized ref-
erence sample (normally the average of the control samples)
using these invariant probe sets. Probe sets with large pos-
itive shifts represent the most upregulated genes, and probe
sets with large negative shifts represent the most downreg-
ulated genes. When ranking the most up/downregulated
genes between groups of biological replicates, a consensus
of all possible pairwise comparisons between the biological
replicates is used to produce a robust ranking.
Comparative Gene Expression Proﬁling of
Cancer in Keratinocytes and Melanocytes:
Results and Discussion
New aspects of this analysis of microarray data were com-
bining the analysis of gene expression data from a genet-
ically related mouse model of multi-step cancer with the
analysis of human melanoma data, and using the PRNP to
prioritize candidate genes. Application of the PRNP method
to the mouse SCC model samples and the human me-
lanoma data is illustrated in Fig 6. Up/downregulated genes
1Pelz R, Kulesz-Martin M, and Sears, R: Non-linear normal-
ization of microarray data using invariant probe sets. In preparation.
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were selected based on the magnitude of their positional
shifts found using PRNP (Fig 6A). The list of relevant up/
downregulated genes was refined by requiring that genes
be consistently up/downregulated in each mouse keratin-
ocyte-initiated cellular precursor clone of SCC, and in each
of the malignant SCC cellular derivatives, as well as being
consistently up or downregulated in each human melanoma
(Fig 6B). After eliminating genome duplications between
mouse and human and probe set redundancies, 27 genes
were found to be upregulated and 13 downregulated ac-
cording to all three of the comparisons above. The 40 re-
trieved genes that fit these criteria are shown in Table I. Of
27 upregulated genes, 13 are cancer associated as refer-
enced in Pubmed. In addition, three of the remaining 27
genes interact with cancer-related proteins or are homo-
logues of other cancer-related genes, resulting in 16 of 27
retrieved genes being cancer related. Five of the upregu-
lated known genes have not been reported as cancer re-
lated. Six of the upregulated genes are unknown (indicated
in Table I by difference in rank order from greatest to least).
Of the 13 downregulated genes, all known genes, nine are
referenced in other cancer-related publications.
Several of the higher-ranking upregulated genes in the
current PRNP analysis were also extracted by the standard
fold change method reported previously in Hoek et al
(2004). These include insulin-like growth factor-binding pro-
tein 2 (Igfbp2), procollagen, type IX, a3 (Col9a3), fibronectin
1 (Fn1), and transmembrane 4 superfamily member 13
(Tm4sf13). Igfbp2 is involved with the regulation of cell
growth and maintenance. Col9a3 plays an integral role in
cell adhesion and is a structural constituent of the extra-
cellular matrix. Fn1 is involved with the transforming growth
factor-b signaling pathway and affects a variety of cellular
activities including cell adhesion, metabolism, and wound
healing. Tm4sf13 is an integral plasma membrane protein
involved in signal transduction regulating cell development,
activation, growth, and motility.
Several other genes not previously identified from these
models were highlighted using PRNP. Upregulated ones in-
clude: vitamin D receptor (Vdr), a DNA-binding transcription
factor involved in calcium ion transport and homeostasis,
p300/CBP-associated factor (Pcaf), a histone acetyltransf-
erase involved in transcription regulation, and pleckstrin
homology domain interacting protein (Phip), a protein-bind-
ing protein in the insulin receptor signaling pathway. The
majority of the downregulated genes identified have already
been discussed previously in multiple cancer publications.
They include: interleukin 24 (Il24) and interleukin 1 receptor
antagonist (Il1ra), cell surface signal transduction proteins
involved in the immune response, CASP8- and FADD-like
apoptosis regulator (Cflar), a caspase involved in the in-
duction and regulation of apoptosis, and cyclin E1 (Ccne1),
a kinase involved in regulating DNA replication initiation
during the cell cycle. The novel perspective gained from this
study is that these genes are altered early in the develop-
ment of cancer, and their altered gene expression is either
retained or exacerbated in metastatic cancer (see fold-
change reports in Table I).
Summary, Conclusions, and Future
Microarray Studies
The current approach combined a biologically well-charac-
terized model and novel computational methods of micro-
array data analysis to greatly reduce the number of
candidate genes for further analysis as cancer diagnostic
or therapeutic targets. The genetically related cells of the
mouse model, comprising non-transformed and early and
late stages of cancer progression, helped narrow the field
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Figure6
Schematic representation of the Pos-
itional Ranking and Normalization
Procedure (PRNP) used to discover
overlapping up- and downregulated
genes in the mouse model of squa-
mous cell carcinoma (SCC) and in
human melanoma. A detailed descrip-
tion of this method will be presented in
another publication (Pelz and Sears, in
preparation). (A) PRNP is based on
comparing the relative order of genes
between two samples. As shown, the
genes in a 291 (normal) sample and a
03C (initiated) sample are sorted based
on expression level. Each gene in the
comparison sample (03C) is given a
rank offset by comparing its rank order
in 03C with its rank order in 291. The
genes are then sorted by these rank
offsets to give downregulated genes on
the left, upregulated genes on the right,
and invariant genes in the middle (bot-
tom schematic). One pairwise compar-
ison is shown, but a consensus of all
possible pairwise comparisons between biological replicates was used to produce a robust ranking of up/downregulated genes between 291 and 03C
samples. (B) Venn diagram showing the strategy for finding overlapping upregulated genes between the early and late stages of the mouse model of
SCC and the human melanoma data. PRNP as illustrated in (A) was applied to compare 291 to 03C, 03C to 03R and human normal to melanoma. The
intersection of all three of the resulting ranked gene lists was determined. This resulted in a ranked list of genes that are upregulated in the early stage
(03C) of the mouse model, further upregulated in the late stage of the mouse model (03R), and also upregulated in the human melanoma data. The
same process was used to identify the ranked list of downregulated genes.
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of human melanoma-associated genes from thousands of
probe sets to 40. Of the 27 upregulated and 13 downreg-
ulated genes known previously, 16 and nine, respectively,
have been previously related to cancer either directly (all but
three) or indirectly through their family member proteins.
Retrieving a high percentage of cancer-related genes by the
comparison of mouse and human cancer samples suggests
that PRNP is an informative method for analyzing microar-
ray data and selecting cancer genes.
The ranking method has the advantage that it is not af-
fected by hybridization discrepancies. Combining this meth-
od with other statistical applications such as Principal
Component Analysis will allow multi-dimensional statistical
separation of ‘‘normal,’’ benign, and malignant cells from the
mouse model. A complete statistical analysis of the mouse
model of SCC will provide a basis for comparison that can
be applied to microarray data from individual human tumors
in order to inform their indolent versus acute course and
consequently, to help plan the strategy of therapy.
Fifteen percent of the genes extracted in this experiment
are unknown or have never been previously related to can-
cer. These are listed by accession number in Table I. An
investigation of these genes may reveal new players in the
pathways of cancer. Knowledge of genes in common
among different types of cancers may elucidate common
cancer targets for future therapy.
At least with respect to occurring early and being main-
tained or exacerbated in malignancy, the genes highlighted
by PRNP fit the paradigm for promising cancer molecular
therapeutic candidates, as discussed at the 2004 Montagna
Symposium by the keynote speaker Brian Druker. The
genes represent changes that occur early (like Bcr/Abl ac-
tivation causal in CML) and are required to sustain the can-
cer. In the future, such targets alone or in combination
promise to permit the same types of remissions in human
solid tumors or epithelia as achieved to date in CML.
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